Categories: News

Phemex Expands Digital Commodities Access With Gold and Silver Trading Initiative

APIA, Samoa, Jan. 30, 2026 /PRNewswire/ — Phemex, a user-first crypto exchange, has launched a week-long spot trading initiative focused on digital precious metals, reflecting growing market interest in tokenized gold and silver as components of diversified digital portfolios. The initiative runs from January 29 to February 5, 2026, and features a total incentive pool exceeding $70,000.

- Advertisement -

This campaign focuses on spot trading pairs backed by precious metals, including PAXG, XAUT, and SLVON, aiming to encourage broader participation in commodity-linked digital assets while expanding the role of non-crypto-native instruments within on-chain trading environments. As global investors increasingly seek alternatives that combine the liquidity of crypto markets with the stability characteristics of traditional assets, tokenized metals are emerging as a bridge between the two systems.

- Advertisement -

Open to all Phemex users, with a particular emphasis on those new to spot precious metals trading, the initiative introduces multiple participation pathways designed to lower entry barriers and promote sustained engagement. Eligible users can earn rewards by reaching defined trading activity thresholds, with a total incentive pool distributed across volume-based participation, trading consistency, and first-time engagement.

- Advertisement -

According to Phemex, the initiative reflects a broader strategic direction. By expanding access to asset-backed instruments alongside core crypto products, the exchange aims to support more balanced portfolio construction and long-term participation across market cycles.

- Advertisement -

As part of its evolving multi-asset ecosystem, Phemex continues to integrate digital representations of traditional assets, reinforcing its commitment to providing users with diverse tools to navigate an increasingly convergent global financial landscape.

- Advertisement -

About Phemex

- Advertisement -

Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.

- Advertisement -

For more information, please visit: https://phemex.com/

- Advertisement -

Photo – https://mma.prnewswire.com/media/2873247/20260130_131915.jpg
Logo – https://mma.prnewswire.com/media/2819516/Phemex_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/phemex-expands-digital-commodities-access-with-gold-and-silver-trading-initiative-302674840.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

47 minutes ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

47 minutes ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

47 minutes ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

48 minutes ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

48 minutes ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

48 minutes ago